US Patent

US10314780 — Drippable opthalmic bimatoprost gel

Method of Use · Assigned to MEDPROJECT PHARMA-ENTWICKLUNGS-UND VERTRIEBSGESELLSCHAFT MBH · Expires 2036-06-08 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a drippable ophthalmic gel formulation containing bimatoprost.

USPTO Abstract

The invention refers to a drippable ophthalmic gel, said gel having composition comprising bimatoprost in an amount of 0.003 to 0.03% by weight, polyacrylate in an amount of >0.2% by weight, povidone (PVP), dextrane, polyethylene glycols (PEG), carboxymethyl cellulose (CMC) or poly(vinyl alcohol) (PVA) in an amount of 0.2 to 10% by weight, an isotonizing agent in an amount to produce an osmolality of 200 to 400 mosml/kg, a salt for adjusting the viscosity in an amount of 0.05 to 0.4% by weight, a base in an amount to adjust the pH to 6 to 8 and excipients normally used in ophthalmic gels, having a viscosity in the range of 200 to 2000 mPa·s.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1295 — Lumigan

Patent Metadata

Patent number
US10314780
Jurisdiction
US
Classification
Method of Use
Expires
2036-06-08
Drug substance claim
No
Drug product claim
Yes
Assignee
MEDPROJECT PHARMA-ENTWICKLUNGS-UND VERTRIEBSGESELLSCHAFT MBH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.